• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接种破伤风类毒素、白喉类毒素和无细胞百日咳疫苗(Tdap)后出现的不良反应——阿瑟氏反应

Arthus Reaction as an Adverse Event Following Tdap Vaccination.

作者信息

Pool Vitali, Mege Larissa, Abou-Ali Adel

机构信息

Sanofi Pasteur Inc., Discovery Drive, Swiftwater, PA 18370, USA.

Sanofi Pasteur SA, 14 Espace Henry Vallée, 69007 Lyon, France.

出版信息

Vaccines (Basel). 2020 Jul 14;8(3):385. doi: 10.3390/vaccines8030385.

DOI:10.3390/vaccines8030385
PMID:32674495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7563237/
Abstract

Repeat administration of tetanus toxoid-containing vaccines has rarely been associated with Arthus phenomenon, an immune-complex reaction. In the US, since 2013, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines (Tdap) have been recommended for administration during each pregnancy. Separately, in 2019, one Tdap was approved for repeat administration in adults in the US. We aimed to describe trends in spontaneously reported Arthus reactions following Tdap in the US and to assess the risk of this phenomenon in persons receiving Tdap repeatedly. We reviewed Arthus reports in the Vaccine Adverse Events Reporting System (VAERS), 1990-2018. Reporting rates were estimated using Tdap doses distributed data. A systematic literature review was conducted in MEDLINE for any Arthus cases reported in Tdap clinical trials and observational studies published between 2000 and 2019. We found 192 Arthus reports in VAERS after any vaccine, of which 36 occurred after Tdap and none were reported during pregnancy. The Arthus reporting rate was estimated at 0.1 per million doses distributed. We identified eight published studies of Tdap administration within five years after a previous dose of tetanus toxoid-containing vaccine; no Arthus cases were reported. We conclude that Arthus reaction following Tdap is extremely rare. Increasing frequency of repeat Tdap administration in adults in the US did not result in a detectable increase in reporting rates of this phenomenon, confirming the favorable safety profile of Tdap.

摘要

重复接种含破伤风类毒素疫苗很少与阿瑟斯现象(一种免疫复合物反应)相关。在美国,自2013年以来,破伤风类毒素、减毒白喉类毒素和无细胞百日咳疫苗(Tdap)被推荐在每次怀孕期间接种。另外,2019年,一种Tdap在美国被批准用于成人重复接种。我们旨在描述美国接种Tdap后自发报告的阿瑟斯反应趋势,并评估反复接种Tdap人群中出现这种现象的风险。我们回顾了1990 - 2018年疫苗不良事件报告系统(VAERS)中的阿瑟斯报告。报告率使用已分发的Tdap剂量数据进行估算。在MEDLINE中对2000年至2019年发表的Tdap临床试验和观察性研究中报告的任何阿瑟斯病例进行了系统的文献综述。我们在VAERS中发现了192例接种任何疫苗后的阿瑟斯报告,其中36例发生在接种Tdap后,且孕期无人报告。阿瑟斯报告率估计为每百万剂分发量中有0.1例。我们确定了八项关于在先前接种含破伤风类毒素疫苗后五年内接种Tdap的已发表研究;未报告阿瑟斯病例。我们得出结论,接种Tdap后的阿瑟斯反应极为罕见。美国成人中重复接种Tdap的频率增加并未导致该现象报告率出现可检测到的上升,证实了Tdap良好的安全性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d0/7563237/f7d23b739e39/vaccines-08-00385-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d0/7563237/c1b4bd9d704e/vaccines-08-00385-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d0/7563237/f7d23b739e39/vaccines-08-00385-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d0/7563237/c1b4bd9d704e/vaccines-08-00385-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2d0/7563237/f7d23b739e39/vaccines-08-00385-g002.jpg

相似文献

1
Arthus Reaction as an Adverse Event Following Tdap Vaccination.接种破伤风类毒素、白喉类毒素和无细胞百日咳疫苗(Tdap)后出现的不良反应——阿瑟氏反应
Vaccines (Basel). 2020 Jul 14;8(3):385. doi: 10.3390/vaccines8030385.
2
Safety review of tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccines (Tdap) in adults aged ≥65 years, Vaccine Adverse Event reporting System (VAERS), United States, September 2010-December 2018.65 岁及以上成年人用破伤风类毒素、白喉类毒素、无细胞百日咳疫苗(Tdap)的安全性审查,美国疫苗不良事件报告系统(VAERS),2010 年 9 月至 2018 年 12 月。
Vaccine. 2020 Feb 5;38(6):1476-1480. doi: 10.1016/j.vaccine.2019.11.074. Epub 2019 Dec 26.
3
Adverse events after tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine administered to adults 65 years of age and older reported to the Vaccine Adverse Event Reporting System (VAERS), 2005-2010.2005-2010 年向疫苗不良事件报告系统(VAERS)报告的 65 岁及以上成年人接种破伤风类毒素、白喉类毒素和无细胞百日咳(Tdap)疫苗后的不良事件。
Vaccine. 2011 Nov 21;29(50):9404-8. doi: 10.1016/j.vaccine.2011.05.100. Epub 2011 Sep 13.
4
Enhanced surveillance of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines in pregnancy in the Vaccine Adverse Event Reporting System (VAERS), 2011-2015.2011 - 2015年疫苗不良事件报告系统(VAERS)中对孕期破伤风类毒素、白喉类毒素减少及无细胞百日咳(Tdap)疫苗的强化监测
Vaccine. 2016 Apr 29;34(20):2349-53. doi: 10.1016/j.vaccine.2016.03.049. Epub 2016 Mar 22.
5
Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.65 岁及以上成年人接种破伤风类毒素、白喉类毒素和无细胞百日咳疫苗(Boostrix(®)):两项随机试验的结果。
Vaccine. 2012 Feb 21;30(9):1721-8. doi: 10.1016/j.vaccine.2011.12.055. Epub 2011 Dec 31.
6
Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).预防青少年破伤风、白喉和百日咳:破伤风类毒素、白喉类毒素含量降低的无细胞百日咳疫苗的使用——免疫实践咨询委员会(ACIP)的建议
MMWR Recomm Rep. 2006 Mar 24;55(RR-3):1-34.
7
U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007.美国青少年和成人破伤风、白喉和无细胞百日咳疫苗上市后安全性监测:2005-2007 年。
Vaccine. 2013 Feb 27;31(10):1447-52. doi: 10.1016/j.vaccine.2012.10.097. Epub 2012 Nov 8.
8
Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.青少年百日咳的预防:破伤风类毒素、白喉类毒素减少量及无细胞百日咳(Tdap)疫苗的使用建议
Pediatrics. 2006 Mar;117(3):965-78. doi: 10.1542/peds.2005-3038. Epub 2005 Dec 28.
9
Reactogenicity and immunogenicity of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant and nonpregnant women.破伤风类毒素、白喉类毒素和无细胞百日咳疫苗(Tdap)在孕妇和非孕妇中的反应原性和免疫原性。
Vaccine. 2018 Oct 8;36(42):6354-6360. doi: 10.1016/j.vaccine.2018.07.012. Epub 2018 Sep 13.
10
Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.用于青少年和成人的破伤风、白喉和五组分百日咳联合疫苗。
JAMA. 2005 Jun 22;293(24):3003-11. doi: 10.1001/jama.293.24.3003. Epub 2005 Jun 2.

引用本文的文献

1
Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant.孕妇疫苗接种指南:应对 COVID-19 和奥密克戎变异株。
Med Sci Monit. 2024 Jan 17;30:e942799. doi: 10.12659/MSM.942799.
2
Immunogenicity and Reactogenicity in Q Fever Vaccine Development.在 Q 热疫苗开发中的免疫原性和反应原性。
Front Immunol. 2022 May 26;13:886810. doi: 10.3389/fimmu.2022.886810. eCollection 2022.
3
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.疫苗与过敏反应:过去、当前的 COVID-19 大流行及未来展望。

本文引用的文献

1
Vital Signs: Burden and Prevention of Influenza and Pertussis Among Pregnant Women and Infants - United States.生命体征:美国孕妇和婴儿中流感和百日咳的负担和预防。
MMWR Morb Mortal Wkly Rep. 2019 Oct 11;68(40):885-892. doi: 10.15585/mmwr.mm6840e1.
2
Arthus Reaction.阿瑟斯反应
J Emerg Med. 2019 Apr;56(4):450-451. doi: 10.1016/j.jemermed.2018.12.047. Epub 2019 Feb 27.
3
Influenza and Tdap Vaccination Coverage Among Pregnant Women - United States, April 2018.孕妇流感和 Tdap 疫苗接种率 - 美国,2018 年 4 月。
Allergy. 2021 Jun;76(6):1640-1660. doi: 10.1111/all.14840. Epub 2021 Jun 4.
MMWR Morb Mortal Wkly Rep. 2018 Sep 28;67(38):1055-1059. doi: 10.15585/mmwr.mm6738a3.
4
Safety of repeated doses of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine in adults and adolescents.成人和青少年破伤风类毒素、白喉类毒素和无细胞百日咳疫苗重复剂量的安全性。
Pharmacoepidemiol Drug Saf. 2018 Aug;27(8):921-925. doi: 10.1002/pds.4569. Epub 2018 Jun 3.
5
Association of Tdap Vaccination With Acute Events and Adverse Birth Outcomes Among Pregnant Women With Prior Tetanus-Containing Immunizations.既往接种过含破伤风疫苗的孕妇中,百白破疫苗接种与急性事件及不良分娩结局的关联
JAMA. 2015 Oct 20;314(15):1581-7. doi: 10.1001/jama.2015.12790.
6
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS).疫苗不良事件报告系统(VAERS)中的安全性监测。
Vaccine. 2015 Aug 26;33(36):4398-405. doi: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22.
7
Best vaccination practice and medically attended injection site events following deltoid intramuscular injection.三角肌肌内注射后的最佳疫苗接种实践及医疗处理的注射部位事件
Hum Vaccin Immunother. 2015;11(5):1184-91. doi: 10.1080/21645515.2015.1017694.
8
Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum.联合低抗原含量破伤风、白喉和无细胞百日咳(Tdap)疫苗相关结节性红斑:病例报告及疫苗相关性结节性红斑综述。
Dermatol Ther (Heidelb). 2013 Dec;3(2):191-7. doi: 10.1007/s13555-013-0035-9. Epub 2013 Nov 1.
9
Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women--Advisory Committee on Immunization Practices (ACIP), 2012.更新的孕妇破伤风类毒素、白喉类毒素和无细胞百日咳疫苗(Tdap)使用建议——免疫实践咨询委员会(ACIP),2012 年。
MMWR Morb Mortal Wkly Rep. 2013 Feb 22;62(7):131-5.
10
Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose.在先前接种一剂 Tdap(吸附破伤风类毒素、白喉类毒素和无细胞百日咳疫苗)后 4-5 年,对青少年和成年人进行破伤风类毒素、减量白喉类毒素和无细胞百日咳疫苗吸附(Tdap)加强免疫的耐受性和抗体应答。
Vaccine. 2011 Oct 26;29(46):8459-65. doi: 10.1016/j.vaccine.2011.07.068. Epub 2011 Jul 29.